* Report out on 21 October at 08:00 CEST * Q3e sales of SEK 10m (32m), no machine deliveries in the ...
Redeye comments on the updated clinical data from the phase I study combining the oncolytic virus TB...
Redeye comments on the phase I data generated from a phase I study combining MesoPher with mitazalim...
* Seasonally weak quarter * We cut '25e-'27e adj. EBITA by 2% Trading ~20% below current peers on '2...
Redeye provides a preview of Litium’s Q3 results, set to be released on 23 October.
* Q3e: soft growth but GM improvements * Minor estimate cuts on FX and product mix * Trading at '26e...
Hanza har slutfört förvärvet av Milectria, en finsk kontraktstillverkare med hög exponering mot förs...
Redeye leaves a short comment following OncoZenge’s announcement that UCLA has enrolled the first pa...
Redeye updates its estimates and fair value range following Enviro’s rights issue, where we have als...
Redeye is encouraged by today’s news of Nekkar’s subsidiary Intellilift and its JV, InteliWell, anno...
Redeye is positive about the results from CLS’s study at Skåne University Hospital.
Redeye provides its initial comments on Xspray following last night’s press release confirming a Com...
Redeye takes a positive stance towards Addnode’s acquisition of SolidCAD.
* Q3 sales -36% vs cons, EBIT SEK -3m vs cons 91m * Main reason is delayed deliveries, Q3 order inta...
Redeye comments on Invisio’s preliminary announcement of Q3-results which were lower than expected o...
